Finance

Lists
GUTS:NASDAQ
Fractyl Health Inc
$0.65
+1.28%
(+0.0082) 1D
Sep 10, 3:38:22 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GUTS...
Open
$0.67
High
$0.67
Low
$0.64
Mkt. cap
103.18M
Avg. vol.
1.40M
Volume
550.86K
52-wk high
$2.44
52-wk low
$0.38
EPS
-$1.12
Shares outstanding
159.18M
No. of employees
100
Open
$0.67
High
$0.67
Low
$0.64
Mkt. cap
103.18M
Avg. vol.
1.40M
Volume
550.86K
52-wk high
$2.44
52-wk low
$0.38
EPS
-$1.12
Shares outstanding
159.18M
No. of employees
100
News stories
From web sources and news partners
Profile
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
About Fractyl Health Inc
CEO-
Employees100
Founded2010
HeadquartersBurlington, Massachusetts, United States
SectorMedical device
Websitefractyl.com
Analyst ratings
Based on 5 analysts giving stock ratings to GUTS in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GUTS in the last 3 months.
Highest
Current $0.65
$8.00 (+1,134.19%)
Average
$4.80 (+640.51%)
Lowest
$2.00 (+208.55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
$4.00
+517.1%
09/02/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$8.00
+1,134.2%
09/02/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$2.00
+208.5%
09/01/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$8.00
+1,134.2%
08/12/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$2.00
+208.5%
08/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17.46M
16.49M
15.60M
13.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.24M
6.79M
5.22M
5.28M
Operating expense
22.69M
23.28M
20.82M
19.10M
Total operating expenses
22.69M
23.28M
20.82M
19.10M
Operating income
-22.69M
-23.28M
-20.82M
-19.10M
Other non operating income
-21.21M
-20.19M
30.06M
-5.49M
EBT including unusual items
-45.60M
-43.73M
9.22M
-25.54M
EBT excluding unusual items
-43.74M
-42.83M
9.83M
-24.16M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45.60M
-43.73M
9.22M
-25.54M
Net profit margin
-
-
-
-
Earnings per share
-0.71
-0.07
-0.13
-0.12
Interest and investment income
166.00K
645.00K
593.00K
431.00K
Interest expense
-
-
-
-
Net interest expenses
166.00K
645.00K
593.00K
431.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.40M
-23.00M
-20.54M
-18.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps